Grifols, Brookfield
Grifols (NASDAQ:GRFS) dropped 3% after a report that Brookfield (BAM) is delaying a takeover bid due to issues raising money ...
EST Brookfield still pursuing Grifols (GRFS) deal, Bloomberg reports Published first on TheFly – the ultimate source for ...
Brookfield Asset Management is in talks with several investment funds as part of the proposed acquisition of the Spanish blood plasma company Grifols SA. This is reported in a Brookfield press ...
Brookfield fund has failed to raise the nearly €10,000 million needed to acquire 70% of the company and restructure the debt.
Four people were taken to the hospital after a crash in Brookfield on Saturday. Emergency crews responded to the 100 block of Junction Road around 1 p.m. for a crash with injuries. According to ...
Canadian fund Brookfield reaffirmed its interest in a potential takeover of Spanish drugmaker Grifols and requested more time to complete due diligence for its possible bid, two sources with ...
The company has a 50 day moving average of $8.82 and a 200 day moving average of $7.77. Grifols has a twelve month low of $5.30 and a twelve month high of $12.15. Get Grifols alerts: Grifols ...
Global healthcare company Grifols has partnered with BARDA, the Biomedical Advanced Research and Development Authority, to develop the first immune therapy eye drops to prevent the long-term ...
Overview: Grifols, S.A. is a plasma therapeutic company operating in Spain, the United States, Canada, and internationally with a market cap of approximately €6.40 billion. Operations: Grifols ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback